A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Latest Information Update: 29 Jun 2025
At a glance
- Drugs Trospium chloride/xanomeline (Primary) ; Xanomeline (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms ADAGIO-2
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 13 Jun 2025 New trial record